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Prolonged Eosinophil Accumulation in Allergic
Lung Interstitium of ICAM-2-Deficient Mice
Results in Extended Hyperresponsiveness
LFA-1 (CD11a/CD18) (Springer, 1990; de Fougerolles
and Springer, 1992).
The overlapping yet distinct expression patterns of
ICAM-1 and ICAM-2 in human tissue suggest special-
ized roles for both molecules: ICAM-2 is constitutively
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hesion of lymphocytes and monocytes to resting endo-
thelial cells, while ICAM-1 mediates one third of theSummary
binding (Dustin and Springer, 1988; de Fougerolles et
al., 1991; Xu et al., 1994).ICAM-2-deficient mice exhibit prolonged accumula-
Based on the expression patterns of ICAM-2 and
tion of eosinophils in lung interstitium concomitant
ICAM-1, it has been hypothesized that ICAM-2 is im-
with a delayed increase in eosinophil numbers in the
portant for leukocyte trafficking in uninflamed tissues,
airway lumen during the development of allergic lung
as in lymphocyte recirculation, whereas induction of
inflammation. The ICAM-2-dependent increased and
ICAM-1 on endothelium and other cells by inflammatory
prolonged accumulation of eosinophils in lung intersti- cytokines may increase cell-cell interactions and leu-
tium results in prolonged, heightened airway hyperre- kocyte extravasation at inflammatory sites (Springer,
sponsiveness. These findings reveal an essential role 1994). ICAM-1-deficient mice are resistant to septic
for ICAM-2 in the development of the inflammatory shock (Xu et al., 1994) and show attenuated ischemia
and respiratory components of allergic lung disease. reperfusion injury (Connolly et al., 1996; Kelly et al., 1996;
This phenotype is caused by the lack of ICAM-2 ex- Soriano et al., 1996).
pression on non-hematopoietic cells. ICAM-2 defi- Airway hyperresponsiveness is one of the central fea-
ciency on endothelial cells causes reduced eosinophil tures of asthma (Cockcroft et al., 1977). Reversible nar-
transmigration in vitro. ICAM-2 is not essential for lym- rowing of the airways is generally observed in associa-
phocyte homing or the development of leukocytes, tion with pulmonary inflammation (Gelfand and Irvin,
with the exception of megakaryocyte progenitors, 1997). The inflammatory infiltrate in the lung is character-
which are significantly reduced. ized by an increase in number of eosinophils, which are
central to the pathogenesis of the disease (Gleich et
Introduction al., 1988). The recruitment of these cells to the site of
inflammation is controlled by adhesive interactions to
Leukocyte migration from the blood into surrounding endothelial, epithelial, and other tissue resident cells.
tissue is critically regulated by the interplay of several In mouse models of allergic airway inflammation, the
families of adhesion receptors (Butcher, 1991; Lasky, recruitment of leukocyte subsets to the lung can be
1992; Springer, 1994). Essential to this adhesion cas- monitored at different anatomical sites: interstitial (peri-
cade is the interaction between immunoglobulin (Ig) cell vascular and/or airway wall) and airway lumen. These
adhesion receptors expressed on endothelium and inte- anatomical locations correspond to different degrees of
grins on leukocytes. The Ig superfamily members inter- leukocyte migration, from essential blood vessel extrav-
cellular adhesion molecules (ICAM)-1 and ICAM-2 are asation, navigation through tissue interstitium, to trans-
products of distinct and homologous genes and were epithelial exit to airway lumen. Even more importantly,
initially identified by their ability to bind the b2 integrin these models also make it possible for us to study a
physiological endpoint that is essential in disease: bron-
chial hyperresponsiveness (BHR).7 To whom correspondence should be addressed (e-mail: gerwin@
mpi.com [N. G.], gutierrez@mpi.com [J. C. G.-R.]). The biological functions of ICAM-2 in vivo have not
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Figure 1. Targeting of the ICAM-2 Gene
(A) Design of the replacement vector. Diagrams depict the structures of the targeting vector (a), the ICAM-2 gene (b), and the mutated allele
(c). The replacement vector contains the PGK-neor gene cassette inserted in exon 2, flanked by 5.2 and 1.1 kb of DNA from the ICAM-2 locus.
The probe (a PstI/NheI cDNA fragment) is an external probe used for Southern hybridization. Restriction sites: X, XbaI; E, EcoRI; H, HindIII;
B, BamHI.
(B) Southern blot analysis of tail DNA isolated from a litter of 6 mice from a heterozygous intercross. The 5.4 kb wild-type and 5.0 kb targeted
allele BamHI fragments identified by the probe are indicated. The genotypes of the tested mice are shown on top of each lane.
(C) Immunohistochemical analysis of ICAM-2 expression in lung. Frozen sections of lungs from wild-type (WT; top) and ICAM-22/2 mice (KO;
bottom) were stained with polyclonal a-ICAM-2 serum using an avidin-biotin peroxidase system in conjugation with a hematoxylin counterstain.
ICAM-2 expression is visible as brown staining on vascular endothelium and alveolar capillaries (magnifications, 3100 and 3400).
(D) Flow cytometry analysis of ICAM-2 expression on lymphocytes. Thymocytes (top) and lymph node cells (bottom) from wild-type (WT) and
ICAM-22/2 mice (ICAM-2 KO) were stained with a-ICAM-2 MAb (gray histogram) or an isotype-matched negative control MAb (white histogram)
and subjected to flow cytometry.
been investigated previously. Here, we report the gener- Southern blot analysis, and microinjected into C57BL/6
blastocysts. One chimeric male transmitted the mutantation of mice that are deficient for ICAM-2 by homolo-
gous recombination in embryonic stem (ES) cells. We allele to his offspring. Southern blot analysis of tail
biopsies revealed the presence of homozygous mutanthave used these mutant mice to study the specific role
of ICAM-2 during an inflammatory response in a mouse mice (ICAM-22/2; Figure 1B) at the expected ratios.
ICAM-22/2 mice appeared normal in size, general health,model of allergic lung inflammation. We have also in-
vestigated the essential roles of ICAM-2 in vivo in the fertility, and longevity.
development of hematopoietic cells and in lympho- Immunohistochemical staining of frozen sections of
cyte homing. wild-type mice showed ICAM-2 positive staining in lung
on vascular endothelium and alveoli but not in the large
Results airways (Figure 1C). ICAM-2 expression in kidney, liver,
and spleen resembled the expression pattern previously
reported for human tissues (de Fougerolles et al., 1991;Generation of ICAM-2-Deficient Mice
To generate ICAM-2-deficient mice, a gene replacement data not shown). In contrast, ICAM-22/2 mice were com-
pletely negative for ICAM-2 staining in these organsvector was made in which exon 2 (Xu et al., 1992) is
interrupted by insertion of the PGKneo cassette (Figure (Figure 1C; data not shown). Flow cytometry analysis of
thymocytes, T and B lymphocytes, as well as myeloid1A). J1 ES cells were transfected, selected, screened by
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Table 1. Summary of Hematopoietic Development and Function Assays Performed with ICAM-22/2 Mice
Activity Tested Readout Result
NK cell cytotoxicity (n 5 3)a %YAC-1 lysis (6SEM); WT: 10 (6 1.0), 20 (6 1.5), 24 (6 2.2), 35 (6 4.2)
E / T ratio: 11, 33, 100, 200 KO: 10 (6 1.2), 20 (6 1.1), 25 (6 3.0), 36 (6 3.0)
LAK cell cytotoxicity (n 5 3)a %YAC-1 lysis (6SEM); WT: 5 (6 0.9), 15 (6 1.8), 32 (6 3.7), 56 (6 3.1)
E / T ratio: 7, 22, 66, 200 KO: 5 (6 0.4), 15 (6 1.0), 34 (6 2.0), 56 (6 1.8)
CFU-GM (n 5 6)b Number of CFU-GM per 106 WT: 2770 (6 794)
bone marrow (BM) cells (6SEM) KO: 2088 (6 596) p 5 0.51
CFU-MKc Number of CFU-MK per 2 3 105 WT: 0, 8.5 (6 0.7), 9.5 (6 2.1), 13.5 (6 0.7)
BM cells (6SD); KO: 0, 1.5 (6 0.7), 2 (6 0), 3.5 (6 0.7)
IL-3 conc: 0, 25, 50, 100 ng/ml
Immature megakaryocytesc Number of single megakaryocytes IL-6: WT: 22 (6 2.1), 49 (6 2.1), 41 (6 1.4), 34 (6 2.1)
per 5 3 104 fract. BM cells (6SD) KO: 8 (6 1.4), 15 (6 1.4), 14 (6 0), 12 (6 1.4)
IL-6 conc: 0, 25, 50, 100 ng/ml mTPO: WT: 22 (6 2.1), 67 (6 2.1), 75 (6 0.7), 54 (6 1.5)
mTPO conc: 0, 25, 50, 100 ng/ml KO: 8 (6 1.4), 12 (6 0), 18 (6 1.4), 15 (6 0.7)
Platelet count (n 5 15) Platelet number 3 105/mm3 (6SEM) WT: 9.5 (6 3.7) KO: 7.5 (6 3.8) p 5 0.72
Bleeding times (n 5 15) Bleeding time (sec) (6SEM) WT: 70.9 (6 12.9) KO: 63.3 (6 8.2) p 5 0.63
a In one representative out of four experiments.
b Each assay was performed in duplicate.
c In one representative out of three experiments.
cells from a variety of organs of the mutant mice con- the ICAM-2 deficiency (Table 1; data not shown). In
addition, bleeding times in wild-type and knockout micefirmed the absence of ICAM-2 expression, whereas wild-
type littermates showed low but clear expression in were not significantly different, as shown in Table 1.
these leukocyte types (Figure 1D; data not shown). In
ICAM-22/2 leukocytes, ICAM-1 expression was not in- Severely Compromised Eosinophil Accumulation
in Lung Allergic Inflammation in ICAM-22/2 Micecreased compared to wild-type hematopoietic cells
(data not shown). To address the role of ICAM-2 in the migration of dif-
ferent types of leukocytes to sites of an inflammatory
response, we used a mouse model of ovalbumin (OVA)-Effects of ICAM-2 Mutation on Hematopoietic
Cell Development induced lung allergic inflammation in which preim-
munized mice (day 1) were challenged by repeatedIn ICAM-22/2 mice, no significant differences were de-
tected in the total leukocyte and red blood cell counts aerosolized exposure to OVA (day 8 and days 15±21,
daily). This model is characterized by macrophage, lym-or leukocyte subset numbers (data not shown) com-
pared to wild-type mice. phocyte, and eosinophil accumulation in both the lung
interstitium and the airway lumen, in conjunction withNo significant differences between ICAM-22/2 and
wild-type mice were detectable in the endogenous NK development of BHR (Gonzalo et al., 1996a, 1998).
Eosinophil numbers in the airway lumen as deter-cell cytotoxicity in the spleen against NK sensitive
YAC-1 target cells and NK resistant EL-4 target cells mined by bronchoalveolar lavage (BAL) reach their maxi-
mum 3 hr after the antigen challenge on day 21 in this(Table 1; data not shown). We also observed that lym-
phokine-activated killer (LAK) cells in the spleen of mouse model (Gonzalo et al., 1996a; Figure 3A). In ICAM-
2-deficient mice, BAL eosinophil numbers on day 21,ICAM-22/2 and wild-type mice kill YAC-1 and EL-4 target
cells, respectively, with the same efficiency (Table 1; 3 hr after OVA treatment, were reduced by 77.8% as
compared to wild-type mice (Figure 2A). No significantdata not shown).
The numbers of early myeloid progenitor cells in bone reduction in BAL lymphocyte, monocyte, and macro-
phage numbers was detectable.marrow, spleen, and peripheral blood were determined
by colony forming unit-granulocyte/macrophage (CFU-
GM) assays and proved to be equal in ICAM-22/2 and Mechanism of ICAM-2 Controlled Eosinophil
Accumulation in the Airway Lumenwild-type mice (Table 1; data not shown).
Numbers of megakaryocyte progenitors at two differ- Eosinophil numbers in either bone marrow or peripheral
blood after OVA treatment were not significantly differ-ent stages of differentiation were determined using the
colony forming unit-megakaryocyte (CFU-MK) and the ent in ICAM-22/2 and wild-type mice, ruling out the pos-
sibility that ICAM-2 deficiency affects eosinophil devel-single cell megakaryocyte growth assay (Banu et al.,
1995). In the bone marrow of ICAM-22/2 mice, numbers opment.
ICAM-2 does not seem to be essential for lymphocyte,of mIL-3-dependent CFU-MK were clearly reduced,
while mTPO-dependent CFU-MK were affected to a monocyte, or macrophage accumulation in the airway
lumen, since in ICAM-22/2 mice the lymphocyte, mono-lesser extent by the lack of ICAM-2 expression (Table
1; data not shown). In the single cell assay, numbers of cyte, and macrophage infiltrates were not reduced. In
ICAM-22/2 and wild-type mice, the lymphocyte infiltrateIL-6- and mTPO-dependent megakaryoblasts were also
reduced in the ICAM-22/2 mice in comparison to wild- was composed predominantly of T lymphocytes, as
shown by immunostaining of BAL cells with Thy1.2 MAbtype mice (Table 1).
Platelet numbers in untreated mice or after chemo- (data not shown).
The levels of the Th2 cell cytokines IL-4 and IL-5, astherapy-induced thrombocytopenia were unaffected by
Immunity
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Figure 2. Reduced Eosinophil Accumulation
in the Airway Lumen of ICAM-22/2 Mice upon
OVA Treatment Is Controlled by Nonhemato-
poietic Cells
(A) Leukocyte numbers in the BAL 3 hr after
the last OVA administration on day 21. A con-
trol group consists of wild-type mice that
were treated with PBS instead of OVA. Each
circle represents a single wild-type (WT; open
circle; n 5 11) or ICAM-22/2 (KO; closed cir-
cle; n 5 14) mouse. Bars represent the mean
of each group. The reduction in the average
number of eosinophils in ICAM-22/2 mice
compared to wild-type mice is 78% and the
p-value is ,0.001.
(B) Eosinophil numbers in the BAL of bone
marrow reconstituted ICAM-22/2 mice on day
21, 3 hr after OVA treatment. ICAM-22/2 mice
with normal hematopoietic cells were gener-
ated by bone marrow transplantation. After
challenge with OVA or PBS, the number of
eosinophils in the BAL was determined. The
average number of eosinophils in ICAM-22/2
recipient mice (KO; closed circle; PBS: n 5
3; OVA: n 5 9) is reduced by 76% compared
to wild-type recipients (WT, open circle; PBS:
n 5 3; OVA: n 5 5) and the p-value is ,0.005.
(C) Comparison of eosinophil transmigration
across ICAM-22/2 and wild-type endothelial
cells. Numbers of eosinophils that transmi-
grated across wild-type (WT, bEND5; white
bars) and ICAM-2-deficient (KO, bENDI2.3;
gray bars) endothelial cells, which were either
unstimulated (2) or TNFa-stimulated (1), are
shown for one representative experiment out
of four. Bars represent the mean (6 SD) of
six wells.
well as the inflammatory cytokines TNFa and IL-1a, were endothelial ICAM-2 expression in regulating transendo-
thelial eosinophil migration. Endothelial cell lines fromsimilar in mutant and wild-type mice throughout the OVA
treatment (see Experimental Procedures; data not shown). ICAM-22/2 and wild-type mice (brain-derived endotheli-
oma ICAM-22/2 line 3 [bENDI2.3] and bEND5, respec-These results were confirmed by RNase protection
assays (RPA) in which mRNA levels of the cytokines tively; see Experimental Procedures) were generated
and migration of wild-type eosinophils through bothIL-4, IL-5, TNFa, IL-1a, and IFNg were tested in lung
tissue from OVA-treated ICAM-22/2 mice and wild-type types of endothelial cells was tested in an in vitro trans-
endothelial migration assay. Significantly fewer eosino-control mice (data not shown).
To determine whether ICAM-2 expression on T lym- phils transmigrated through ICAM-22/2 endothelium
than through normal endothelial cells (37% reduction;phocytes and/or other leukocyte subsets, which might
regulate eosinophilia, is sufficient to restore eosinophil Figure 2C). Endothelial stimulation with TNFa induced
upregulation of ICAM-1 and VCAM-1 on wild-type andaccumulation in the lung of ICAM-22/2 mice during an
allergic inflammation, we replaced the entire hematopoi- ICAM-22/2 endothelial cells (data not shown) and led to
a slight increase in transmigration through both types ofetic system of ICAM-22/2 mice with wild-type cells using
bone marrow transplantation. On day 21, 3 hr after OVA endothelium (41% and 25% increase in transmigration
through wild-type and ICAM-22/2 endothelial cells, re-treatment, eosinophil numbers in the BAL of ICAM-22/2
mice transplanted with wild-type bone marrow were still spectively; Figure 2C).
76% lower as compared to reconstituted wild-type con-
trol mice (Figure 2B). The engraftment efficiency in Delayed but Not Abrogated Eosinophil
Accumulation in the Airway LumenICAM-22/2 and control mice was monitored by Southern
blot analysis of genomic spleen DNA using a male spe- of ICAM-22/2 Mice
To test if the observed reduction in transmigrationcific hybridization probe (data not shown). The chime-
rism was 80%±100% in 19 out of 20 engrafted animals. through ICAM-22/2 endothelium causes a delay in eosin-
ophil accumulation in the airway lumen or abolishes itAfter we had established that ICAM-2-dependent eo-
sinophil accumulation in the BAL is controlled by non- completely, we examined BAL leukocyte numbers 1, 3,
6, 12, and 72 hr after OVA challenge on day 21 (Figurehematopoietic cells, we specifically studied the role of
Prolonged Eosinophilia in ICAM-22/2 Mice
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Figure 3. Eosinophil Presence in the Airway Lumen Is Delayed and Eosinophil Accumulation in Lung Tissue Is Prolonged in ICAM-22/2 Mice
after OVA Treatment
(A) Time course of eosinophil accumulation in the airway lumen. Eosinophil numbers in BAL of wild-type mice (gray bars) and ICAM-22/2 mice
(black bars) were determined 1, 3, 6, 12, and 72 hr after OVA challenge on day 21 and in untreated mice (0 hr). Bars represent the mean
(6 SEM) of five mice per group (*p , 0.05; **p , 0.005; ***p , 0.005).
(B) Enumeration of eosinophils in lung tissue. To determine the relative eosinophilia in wild-type (gray bars) and ICAM-22/2 mice (black bars)
following OVA challenge, the total number of eosinophils in peribronchiolar fields was counted in five fields of H&E stained sections per mouse
at a magnification of 3400. Bars represent the mean number (6 SEM) of eosinophils per field for each group of mice (n 5 5). The p-value at
12 hr is 0.065.
(C) Assessment of eosinophil activation in lung tissue sections. H&E staining of eosinophil morphology (a and b) and peroxidase staining of
eosinophil granules (c±f) were performed in paraffin-fixed sections of lungs isolated from wild-type (WT) and ICAM-22/2 mice (KO). Panels
a±d show staining of lung sections collected 3 hr after OVA challenge (magnification 3400). EPO staining of eosinophil granules resulted in
a brown reaction product (insets in panels c and d). Panels e and f are photographs of EPO stained lung sections collected at 12 hr.
3A). As seen in previous experiments, BAL eosinophil mice revealed the presence of substantial interstitial
infiltrates in perivascular and peribroncheolar areas innumbers in wild-type mice reached their maximum 3 hr
after OVA treatment and were back to normal levels at wild-type mice as soon as 1 hr after OVA challenge
(relative histological scores [6 SEM] of 3 [6 0.3] and12 hr. In ICAM-22/2 mice, eosinophil accumulation in
the airway lumen was not abrogated but greatly delayed. 2.8 [6 0.6] at 1 hr and 3 hr, respectively). In ICAM-22/2
mice, numbers of interstitial infiltrates increased moreBAL eosinophil numbers in ICAM-22/2 mice increased
very slowly and reached levels comparable to those of slowly and reached their maximum only 3 hr after antigen
challenge (scores of 2.5 [6 0.5] and 3.6 [6 0.3] at 1 hrwild-type mice only after 72 hr. Accumulation of lympho-
cytes and monocytes in the airway lumen was not signifi- and 3 hr, respectively). While the number of infiltrates
started to decrease in wild-type mice 6 hr after OVAcantly delayed in ICAM-22/2 mice and was highest 3 hr
after antigen treatment (data not shown). treatment (scores of 2.3 [6 0.6], 1.8 [6 0.4], and 2.1
[6 0.9] at 6 hr, 12 hr, and 72 hr, respectively), interstitial
infiltrates in ICAM-22/2 mice were not reduced until 72Prolonged Presence of Eosinophil Infiltrates
in Lung Tissue of ICAM-22/2 Mice hr after antigen challenge (scores of 3.2 [6 0.5], 3.2
[6 0.5], and 2.3 [6 0.8] at 6 hr, 12 hr, and 72 hr, respec-after OVA Treatment
To determine whether the delayed eosinophil accumula- tively].
Closer examination of the infiltrate composition re-tion in the airway lumen was due to slower endothelial
transmigration in vivo, we assessed the extent of leuko- vealed that eosinophil numbers in the interstitium par-
alleled the number of infiltrates (Figure 3B). In thecyte migration to the lung interstitium. Hematoxylin and
eosin (H&E) stained lung sections from OVA-treated interstitium of wild-type mice, eosinophil accumulation
Immunity
14
Figure 4. ICAM-2 Expression in Lung Tissue Is Not Altered after
OVA Treatment
The distribution of ICAM-2 protein in wild-type lungs following OVA
treatment was determined by immunohistochemical staining of fro-
zen sections with a-ICAM-2 MAb (a) and a negative control antibody
(b) (magnification 3200).
Figure 5. Prolonged Airway Hyperresponsiveness in ICAM-22/2
Mice
reached a maximum as early as 1 hr after antigen chal-
The degree of bronchoconstriction was measured in wild-type (WT,
lenge and started to decrease at 6 hr. In ICAM-22/2 mice, squares) and ICAM-22/2 mice (KO, diamonds) 1, 3, 6, 12, and 24 hr
maximal eosinophil numbers in the interstitium, which after the last OVA or PBS challenge on day 21. Mice were exposed
were approximately 100% higher than the maximal eo- to an aerosol of methacholine (80 mg/ml) for 1 min and airway
constriction was evaluated for the next 5 min. Results are shownsinophil numbers detected in wild-type interstitium at
as mean (6 SEM) of Penh for n 5 5 mice per time point (*p , 0.05;1 hr, were observed 12 hr after OVA treatment. The
**p , 0.05; ***p , 0.01).observed time course of eosinophil accumulation in the
interstitium also paralleled changes in eosinophil num-
bers in the airway lumen as enumerated by BAL (Figure
We investigated quantitative changes in ICAM-2 ex-3A). Complementary eosinophil distribution between the
pression in whole lung tissue upon OVA treatment usingtwo compartments was demonstrated at 72 hr in ICAM-
cDNA microarray technology. Hybridization of an ICAM-222/2 mice, when eosinophils were no longer detectable
DNA fragment containing microarray with cDNA fromin the interstitium, but reached a corresponding maxi-
untreated as well as OVA-treated wild-type lungs re-mum in BAL.
vealed a 3.5-fold upregulation of ICAM-2 expressionDifferences in numbers as well as activation/degranu-
upon OVA treatment (data not shown).lation of eosinophils between wild-type and ICAM-22/2
mice were assessed by morphological staining (H&E)
Prolonged Airway Hyperresponsivenessand cyanide-resistant eosinophil peroxidase (EPO) stain-
in ICAM-22/2 Miceing of eosinophils in serial sections of OVA-treated lungs
To evaluate if the prolonged and increased accumula-(Figure 3C). Three hours after OVA treatment, equivalent
tion of eosinophils in lung interstitium and the delayednumbers of eosinophils were detected by morphological
presence of eosinophils in the airway lumen causesstaining (Figures 3Ca and 3Cb) and peroxidase staining
changes in airway BHR, we measured bronchoconstric-of granules (Figures 3Cc and 3Cd) in wild-type and
tion in response to methacholine (Mch) provocation inICAM-22/2 mice, which indicates that eosinophils in
OVA-treated mice (Figure 5). BHR was increased in wild-wild-type and mutant mice do not overtly differ in their
type and mutant mice as early as 1 hr after antigenactivation/degranulation status. At 12 hr after OVA treat-
treatment and reached its maximum at 6 hr in wild-typement, both EPO and H&E staining of lung sections re-
mice. While airway hyperresponsiveness returned tovealed widespread eosinophil infiltration in ICAM-22/2
baseline levels in wild-type mice 12 hr after OVA chal-mice but only small infiltrates in wild-type mice (Figures
lenge, BHR remained high in ICAM-22/2 mice. In fact,3Ce and 3Cf; data not shown).
ICAM-22/2 mice were hyperresponsive for at least an-We studied possible correlations between the pheno-
other 48 hr (Figure 5; data not shown). At all time pointstype observed in ICAM-22/2 mice (delayed eosinophil
studied, an overall increase in BHR was observed inaccumulation in the airway lumen and prolonged pres-
ICAM-22/2 mice as compared to wild-type mice.ence of eosinophils in lung interstitium) and the pattern
of ICAM-2 expression in inflamed lung. High expression
of ICAM-2 on lung vascular endothelium and in alveolar In Vivo Homing of Lymphocytes in ICAM-22/2 Mice
To test if ICAM-2 deficiency affects lymphocyte migra-walls was observed before and after OVA treatment by
immunohistochemical staining of tissue sections (Fig- tion to lymph nodes (LN), we traced the in vivo homing
of fluorescently labeled LN cells to peripheral LN, mes-ures 1C and 4). Additional ICAM-2 expression was iden-
tified in some cell clusters in the mononuclear infiltrates. enteric LN, and spleen. In the representative experiment
shown in Figure 6, the absolute numbers of peripheralLittle, if any, ICAM-2 expression was observed with this
method on large airway epithelium, before or after OVA LN cells from ICAM-22/2 and wild-type mice, which homed
to peripheral and mesenteric LN, Peyer's patches, andtreatment.
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underlie the prolonged accumulation of eosinophils in
lung interstitium and their delayed appearance in the
airway lumen; and (2) what are the physiological conse-
quences of this abnormal redistribution of eosinophils
for airway function?
With respect to the first issue, ICAM-2 could control
eosinophil accumulation in the airway lumen by the fol-
lowing mechanisms: (1) by directly mediating adhesive
interactions of eosinophils with components of the lung,
(2) indirectly, by controlling the recruitment of other leu-
kocyte subsets to the inflammatory site, (3) by regulating
the expression and release of activating cytokines and
chemokines, or (4) by regulating eosinophil development
and release from the bone marrow. Here, we show that
ICAM-2 controls eosinophil accumulation in the airway
lumen by direct adhesive interactions. We demonstrate
that in ICAM-22/2 mice, T lymphocyte, monocyte, and
macrophage numbers in the lung are not significantly
reduced (Figure 2A), and levels of cytokines are not
overtly altered (data not shown). Furthermore, we show
that eosinophil numbers in peripheral blood and bone
marrow are not reduced in the mutant mice (data not
Figure 6. Lymphocyte Homing Is Not Affected by the Lack of shown), indicating that ICAM-2 expression on early he-
ICAM-2 Expression
matopoietic progenitor cells and bone marrow endothe-
The homing of wild-type and ICAM-22/2 lymphocytes to peripheral lium is not essential for eosinophil development and
LN of wild-type (WT) and ICAM-22/2 mice (KO) in the resting state
release from the bone marrow.was tested 90 min after injection of donor cells from peripheral LN.
Using bone marrow chimeras (Figure 2B), we demon-Each square represents the total number of either TRITC-labeled
wild-type or Calcein-AM-labeled ICAM-22/2 donor cells detected in strate unequivocally that these critical adhesive in-
the peripheral LN sets of a single recipient mouse, which has either teractions are not mediated by ICAM-2 expressed on
wild-type (WT; white squares) or ICAM-22/2 (KO; gray squares) geno- eosinophils or other leukocytes, but rather by ICAM-2
type. Bars represent the mean of each group (n 5 6). expressed on non-bone marrow±derived cells, presum-
ably on lung resident cells. ICAM-2 expression in lung
tissue seems to be restricted to vascular endothelium,
the spleen (Figure 6; data not shown) in wild-type and which shows high expression of ICAM-2, and to alveolar
ICAM-22/2 recipient mice are not significantly different. walls (Figures 1C and 5). In large airway epithelium,
Labeled wild-type cells (6 SEM) represented 0.44% ICAM-2 expression is detectable neither before nor
(6 0.03%) and 0.45% (6 0.04%) of peripheral LN cells, after OVA treatment. However, we cannot exclude that
0.50% (6 0.05%) and 0.44% (6 0.06%) of mesenteric ICAM-2 is expressed on airway epithelium at levels that
LN cells, and 0.17% (6 0.01%) and 0.18% (6 0.02%) of are not detectable by immunohistochemistry. The ob-
Peyer's patch cells in normal and ICAM-22/2 recipient served upregulation of ICAM-2 mRNA expression in
mice, respectively. Likewise, the lack of ICAM-2 expres- whole lung tissue upon OVA treatment could further
sion on injected lymphocytes from ICAM-22/2 mice did support the requirement of ICAM-2-mediated adhesive
not alter their ability to home to the respective organs interactions during this inflammatory response.
(0.46% [6 0.06%] and 0.44% [6 0.07%] in peripheral Our observation that eosinophil accumulation in the
LN, 0.42% [6 0.05%] and 0.35% [6 0.05%] in mesenteric airway lumen, as monitored by BAL, was delayed in
LN, and 0.15% [6 0.01%] and 0.15% [6 0.01%] in Pey- ICAM-22/2 mice suggests that ICAM-2 specifically con-
er's patch cells of wild-type and ICAM-2 deficient mice, trols the exit of eosinophils to the airway lumen by medi-
respectively). These data were confirmed by the obser- ating epithelial and/or endothelial transmigration of eo-
vation that B and T lymphocyte and myeloid cell subpop- sinophils. The histological analysis of lung tissue at
ulations were equally distributed in LN and Peyer's various time points after OVA treatment revealed that the
patches of resting ICAM-22/2 and wild-type mice (data kinetics of eosinophil accumulation in airway interstitium
not shown). complements that of eosinophil accumulation in the air-
way lumen. While eosinophil infiltrates were comparable
Discussion 3 hr after OVA treatment in wild-type and mutant mice,
they developed more slowly and persisted much longer
The results reported here demonstrate that ICAM-2 in the interstitium of ICAM-22/2 mice as compared to
plays a critical role in eosinophil trafficking and localiza- control mice. Eosinophil infiltrates were most prominent
tion within the lung tissue during lung allergic inflamma- at 12 and 24 hr after antigen challenge in ICAM-2-defi-
tion. These data also highlight the importance of eosino- cient mice, whereas in wild-type mice infiltrates were
phil localization for the development and maintenance almost completely resolved at the same time points.
of BHR. By 72 hr, eosinophils are no longer found in the lung
The data presented in this manuscript raise two points interstitium but are still detectable in the airway lumen
of ICAM-22/2 mice (Figure 3; data not shown). Therefore,for further discussion: (1) which molecular mechanisms
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we propose that ICAM-2 expressed on vascular endo- Although time windows of BHR vary dramatically in
thelium, alveolar walls, and possibly large airway epithe- different models of lung allergic inflammation (Eum et
lium mediates the trafficking of eosinophils through in- al., 1995; Foster et al., 1996; Gonzalo et al., 1996a; Ha-
terstitium and their exit to the lumen of the airways. melmann et al., 1996), the underlying reasons for these
Control of endothelial eosinophil transmigration by ICAM-2 differences have not been elucidated. Instead, the rather
expression was confirmed using an in vitro transendo- different phenotypes have been interpreted based on
thelial migration assay in which eosinophils transmigrate the use of mice with different genetic backgrounds, pro-
normally through wild-type endothelium, but eosinophil tocols of immunization, antigens, etc. Here, we describe
transmigration through ICAM-22/2 endothelium derived a single gene defect that dramatically prolongs BHR in
from the mutant mice is greatly reduced (Figure 2C). mice. This is of critical importance since time windows
The role that ICAM-2 plays in transepithelial migration of hyperresponsiveness in asthmatic patients correlate
is being evaluated at present using a transepithelial che- directly with disease progression and quality of life.
motaxis assay. The impaired migration of eosinophils during lung al-
The second aspect highlighted by the findings re- lergic inflammation contrasts with the unaltered lympho-
ported here is the effect on lung function of the pro- cyte homing to lymph nodes (Figure 6). This is an impor-
longed eosinophil accumulation in the lung interstitium. tant observation, since ICAM-2 had been postulated to
Airway BHR, a major characteristic of allergic asthma, be a critical adhesion receptor controlling steady state
is induced by eosinophils that secrete toxic granular recirculation of lymphocytes, based on in vitro studies
proteins that cause airway damage and smooth muscle and its high constitutive expression on high endothelial
contractility. The BHR response in ICAM-22/2 mice, like venules (Springer, 1994). Results presented here show
in wild-type littermates, developed early after OVA treat- that this is not the case in vivo.
ment and increased further until 6 hr after antigen chal- A number of other phenotypical aspects have been
lenge (Figure 5). While BHR returned to baseline levels examined in these ICAM-22/2 mice and are summarized
12 hr after antigen challenge in wild-type mice, it in- in Table 1. This summary does not represent a detailed
creased further in ICAM-22/2 mice, which indicates that characterization of the phenotypes but is rather in-
the specific location of eosinophils within the lung is tended to serve as a reference guide for investigators
critical for their deleterious effects. In fact, increased in the field. Of special notice is the reduction of mega-
BHR in ICAM-22/2 mice could be demonstrated 24 and karyocyte progenitors in the bone marrow of ICAM-22/2
48 hr after OVA challenge (Figure 5; data not shown), mice. The complete characterization of this finding will
time points at which numbers of eosinophils in the lung be presented elsewhere.
interstitium of mutant mice were still increased. Eosino- In conclusion, our findings establish a critical role for
phils that accumulated in the lung interstitium, but not ICAM-2 in the distribution of eosinophils between the
the eosinophils in the airway lumen, seem to be mostly lung interstitium and airway lumen during the develop-
responsible for the induction/development of BHR. This ment of allergic lung inflammation. Furthermore, we
interpretation is supported by the observation that the have established, using a clean genetic system, that the
recruitment of eosinophils to the airway lumen alone localization of eosinophils within the lung interstitium is
does not induce BHR, and that the development of BHR key for the induction/development of BHR. These results
depends on the localization of eosinophils in the submu- clearly demonstrate that ICAM-2 is not the major media-
cosa of the bronchial epithelium [Eum et al., 1995]. tor of lymphocyte homing in the resting state as antici-
Furthermore, these results correlate well with our pre- pated but plays an essential role in eosinophil trafficking
vious observation, that mice showing reduced interstitial within the lung during an allergic inflammatory response.
eosinophilia, but unaffected BAL eosinophilia after
blockage of the chemokine MCP-5, did not develop BHR Experimental Procedures
(Gonzalo et al., 1998). Likewise, a recent clinical study
Generation of ICAM-2-Deficient Mice(Crimi et al., 1998) has found no significant correlations
The ICAM-2 gene targeting vector was constructed using a 6.3 kbbetween the degree of BHR and the numbers of inflam-
XbaI fragment of genomic DNA that had been isolated from an AKRmatory cells in sputum or BAL or bronchial biopsy. In
mouse strain genomic library (Xu et al., 1992). This DNA fragment,contrast, correlations have been established between
containing exons 1 and 2, was subcloned in pBlueScript (KS). A
the number of eosinophils in the BAL of patients and 1.7 kb EcoRI±HindIII fragment carrying a polyadenylated neomycin
the severity of disease (Azzawi et al., 1990; Howarth et resistance gene (neo-polyA1) under the control of the phosphoglyc-
al., 1994; Djukanovic, 1996). Our study demonstrates ero kinase gene (PGK) promoter (a gift from Drs. E. Li and R. Jae-
nisch, Massachusetts Institute of Technology, Cambridge, MA) wasthat lengthened BHR correlates well with the prolonged
isolated from pKJ1 (Li et al., 1992) and blunted with Klenow. Thispresence of eosinophils in the interstitium and does not
fragment was inserted into the blunted NdeI site in the second exoncorrelate with the peak of eosinophil accumulation in
of the ICAM-2 gene in the 6.3 kb fragment. In parallel, a 2.7 kb
the airway lumen. EcoRI±HindIII fragment of pGEM7 (thymidin kinase [tk]) containing
We could not detect differences between the intersti- the HSVtk gene under the control of the PGK promoter was sub-
tial infiltrates of ICAM-22/2 and wild-type mice when cloned in pBlueScript (KS). Finally, the 8.0 kb XbaI fragment of
ICAM-2 containing the neo insert was subcloned into the XbaI siteeosinophils were identified based on either granule con-
of the pBlueScript (KS) vector containing the tk gene.tent or morphology (Figure 3C). This finding supports
The linearized plasmid was used to transfect J1 ES cells, obtainedthe concept that ICAM-2 controls eosinophil localization
from Drs. E. Li and R. Jaenisch, as described (Li et al., 1992). Recom-rather than eosinophil activation (i.e., cell granule con-
binant clones were identified by Southern blot analysis of BamHI
tent; Lefort et al., 1996; Evans et al., 1997), and that the digested DNA using a 39 flanking probe containing exons 3 and 4
localization of eosinophils in lung tissue is essential for (Figure 1A) and a specific neor gene fragment. Homologous recombi-
nation was observed with a frequency of 1 in 4.5 resistant clones.the development of BHR.
Prolonged Eosinophilia in ICAM-22/2 Mice
17
Embryo manipulations and backcrosses of chimeras to C57BL/6 blood after OVA treatment, equivalent numbers of leukocytes were
pelleted onto glass slides by cytocentrifugation and stained usingmice were performed as described (Bradley, 1987; Li et al., 1992).
a sensitive method dependent on the presence of cyanide-resistant
peroxidase (Boyce et al., 1995). The percentage of eosinophils, lym-Leukocyte Isolation, Counts, Antibody Staining,
phocytes, monocytes, and macrophages was determined by count-and FACS Analysis
ing their number in eight high-power fields (3400 magnification;Blood leukocytes were obtained by cardiac puncture, and complete
total area 0.5 mm2) per area randomly selected and dividing thisblood cell counts were determined using an H*1E Automated Ana-
number by the total number of cells per high-power field. To obtainlyzer (Technicon, Bayer Corp.). Single cell suspensions from ingui-
the absolute number of each leukocyte subtype in the lavage, thesenal, axillary, and cervical LN (peripheral LN), mesenteric LN, bone
percentages were multiplied by the total number of cells recoveredmarrow, spleen, and thymus were prepared, erythrocytes were
from the BAL fluid.lysed, and cell numbers were determined using a hemocytometer.
Lung sections from the different experimental groups of mice wereFor three- color flow cytometry, cells were first preblocked with
prepared as described (Gonzalo et al., 1996b). Sizes of pulmonarypurified a-mouse Fc receptor antibody (a-CD16/32; 2.4G2) from
infiltrates were assessed and scored using a semiquantitative sys-PharMingen (San Diego, CA). Cells were stained with antibodies
tem. Sections were graded from ª0ºÐwhere no infiltrating cells weredirectly conjugated with fluorochrome: a-B220 (RA3-6B2), a-IgM
observed, to ª15ºÐwhere all vessels and bronchioles were sur-(G155-228), a-TCRb (H57-597), a-Thy-1.2 (53-2.1), a-CD4 (L3T4),
rounded by leukocytic infiltrate of at least three cells deep. Eosino-a-CD8 (53-6.7), a-Mac-1 (M1/70), a-Gr-1 (RB6-8C5), a-ICAM-1 (3E2),
phils were counted in H&E stained sections by determining theand irrelevant isotype controls from PharMingen. ICAM-2 staining
number of eosinophils per peribronchiolar field at a magnificationwas done using either fluorochrome-labeled a-ICAM-2 MAb (IC2-
of 3400 in five fields per mouse. All sections were coded and scored3C4; Xu et al., 1996] from PharMingen or unlabeled a-ICAM-2 MAb
blind by at least two observers. Eosinophil granules were detectedkindly provided by Z. Awdeh (Center for Blood Research, Boston,
using the EPO staining method (Boyce et al., 1995).MA) and fluorochrome-labeled a-rat IgG2a,K MAb from PharMingen
as secondary antibody. Dead cells were excluded by staining with
propidium iodide (1 mg/ml final concentration). Samples were ana- ELISA, RPA, and cDNA Microarrays
lyzed using a FACScan instrument (Becton Dickinson and Co., Cytokine levels were determined on day 16, 1 hr, and on day 21, 3
Mountain View, CA). hr after OVA treatment in the BAL fluid using commercial ELISA kits
(Endogen, Cambridge, MA).
At the same time points, cytokine mRNA levels in total lung RNAImmunohistochemical Analysis of ICAM-2 Expression
were analyzed using a RiboQuant RPA kit (PharMingen) as recom-Fixed cryosections (4 mm) of wild-type and ICAM-22/2 mouse tissues
mended by the supplier.were stained with rat monoclonal antibodies directed against
ICAM-2 expression levels in untreated and OVA-treated lungs (dayICAM-2 (PharMingen) using an avidin/biotin staining method as pre-
21, 3 hr) were compared using the cDNA microarray technology asviously described (Gonzalo et al., 1996b). The following control
previously described (Nguyen et al., 1995).slides were included: (1) stained with an isotype-matched negative
control antibody instead of a-ICAM-2 antibody, (2) omission of bio-
tinylated a-rat immunoglobulin, or (3) omission of streptavidin com- Bone Marrow Transplantation Experiments
plex. All slides were counterstained with hematoxylin. Lethally irradiated female ICAM-22/2 and wild-type mice received
5 3 106 bone marrow cells from male wild-type control mice by i.v.
injection. After a recovery period of 5 weeks, the engrafted miceNK Cell Cytotoxicity and LAK Assay
were OVA treated and BAL fluid was analyzed on day 21, 3 hr afterThe endogenous NK cell cytotoxicity was determined by measuring
the last OVA challenge.NK-mediated cytotoxic lysis of YAC-1 target cells using a standard
The engraftment efficiency was assessed by Southern blot analy-51Cr release assay (Wang et al., 1994). All mice were injected i.p.
sis of genomic spleen DNA (10 mg) using the male specific pY2with 100 mg poly I:C 16±24 hr before being sacrificed. LAK cell
hybridization probe (Bernad et al., 1994), kindly provided by Dr. A.activity was assessed by overnight culture of the spleen cells (1 3
Bernad (Universidad Autonoma, Madrid, Spain). The intensity of the107/ml) with mIL-2 (300 U/ml; Genzyme) followed by the standard
male specific signal in each lane was determined by densitometric51Cr release assay (Wang et al., 1994).
analysis. Control lanes for quantitation were loaded with graded
mixtures of male and female genomic spleen DNA (10 mg total).CFU-GM and Megakaryocyte Progenitor Assays
For CFU-GM assays, appropriate numbers of bone marrow, spleen,
and peripheral blood cells from individual mice were plated in meth- Generation of Endothelial Cell Lines
ylcellulose as described (Schmits et al., 1997). and Transmigration Assays
CFU-MK and single cell megakaryocyte growth assays were per- Endothelial cell lines were isolated from ICAM-22/2 mice as pre-
formed as previously described (Banu et al., 1995). In each experi- viously described for the wild-type line bEND5 (RoÈ hnelt et al., 1997).
ment, bone marrow from two mice was pooled. For activation studies, endothelioma cell lines were stimulated with
5 nM recombinant murine TNFa (Bioconcept, Umkirch, Germany)
as indicated.Platelet Assays
Transmigration assays were performed as previously describedPlatelet numbers were determined using a hemocytometer. Throm-
(RoÈ hnelt et al., 1997) using 6.5 mm Transwells (Costar, Bodenheim,bocytopenia was induced by injection of 5-fluorouracil (FU; Sigma,
Germany) with 5 mm pore size. Inserts were coated with lamininSt. Louis, MO; 150 mg/kg i.v.) and platelet recovery was assessed
(Boehringer Mannheim, Mannheim, Germany; 50 mg/ml). 3 3 105by platelet counts on days 3, 7, and 14.
endothelioma cells were seeded on top of each porous filter andFor measurement of bleeding times in unanesthesized mice, 2
cultured for 2 days. On day 3, eosinophils were added on top ofmm of the tail tip were cut off and the tail was placed in isotonic
each filter and the assays were run for 2 hr at 378C and 10% CO2.saline at 378C immediately after injury. Bleeding times were mea-
The 2 hr time point was chosen as it was the earliest time point thatsured from the moment the tail was cut until bleeding stopped
allowed us to harvest enough transmigrated eosinophils to performcompletely.
comparative studies. Migrated eosinophils were collected for cell
counting and analyzed microscopically in Pappenheim-stained cy-Mouse Model of Lung Inflammation
tospins and by FACS analysis. Confluency of the endothelial mono-The mouse model of lung inflammation has been previously de-
layer was confirmed after each assay by Giemsa staining of inserts.scribed (Gonzalo et al., 1996a). Among the BAL cells, T lymphocytes,
Assays were performed as triplicates for each value.B lymphocytes, and mononuclear phagocytes were identified by
Thy1.2 (53-2.1) (PharMingen, San Diego, CA), IgM (II/41) (Phar-
Mingen, San Diego, CA), and Moma-2 (Biosource Int. Camarillo, CA) Evaluation of Bronchoconstriction
The degree of bronchoconstriction was measured 1, 3, 6, 12, 24,staining, respectively, of BAL cell cytospins (Gonzalo et al., 1996b).
To determine eosinophil numbers in bone marrow and peripheral and 48 hr after the last antigen challenge by recording respiratory
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pressure curves by whole body plethysmography (Buxco Technolo- Crimi, E., Spanevello, A., Neri, M., Ind, P.W., Rossi, G.A., and Bru-
sasco, V. (1998). Dissociation between airway inflammation and air-gies, Niskayuna, NY) in response to inhaled methacholine (Mch,
Aldrich, Milwaukee, WI) at a concentration of 80 mg/ml for 1 min, way hyperresponsiveness in allergic asthma. Am. J. Respir. Crit.
Care. Med. 157, 4±9.as described previously (Eum et al., 1995; Tsuyuki et al., 1997). BHR
was expressed as enhanced pause (Penh), a calculated value, which de Fougerolles, A.R., Stacker, S.A., Schwarting, R., and Springer,
correlates with measurement of airway resistance, impedance, and T.A. (1991). Characterzation of ICAM-2 and evidence for a third
intrapleural pressure in the same mouse. Penh 5 (Te/Tr-1) 3 (Pef/ counter-receptor for LFA-1. J. Exp. Med. 174, 253±267.
Pif) (Te, expiration time; Tr, relaxation time; Pef, peak expiratory de Fougerolles, A.R., and Springer, T.A. (1992). Intercellular adhe-
flow; Pif, peak inspiratory flow 3 0.67 5 coefficient) (Gelfand and sion molecule 3, a third adhesion counter-receptor for lymphocyte
Irvin, 1997). The relaxation time is the time it takes for the box function-associated molecule 1 on resting lymphocytes. J. Exp.
pressure to change from a maximum to a user-defined percentage Med. 175, 185±190.
of the maximum. Here, Tr measurement began at the maximum box
Diacovo, T.G., de Fougerolles, A.R., Bainton, D.F., and Springer,pressure and ended at 40%.
T.A. (1994). A functional integrin ligand on the surface of platelets:
intercellular adhesion molecule-2. J. Clin. Invest. 94, 1243±1251.
In Vivo Lymphocyte Homing Assays
Djukanovic, R. (1996). Bronchoscopy as a research tool for the study
For resting state lymphocyte homing assays, peripheral LN cell sus-
of asthma pathogenesis and effects of antiasthma drugs. J. Allergy
pensions from mutant and wild-type mice were labeled with two
Clin. Immunol. 98, S41±S45.
different fluorescent dyes, tetramethyl rhodamine isothiocyanate
Dustin, M.L., and Springer, T.A. (1988). Lymphocyte function associ-(TRITC) and calcein-acetoxymethyl ester (Calcein-AM), as pre-
ated antigen-1 (LFA-1) interaction with intercellular adhesion mole-viously described (Martin and Miller, 1989). An equimolar mixture
cule-1 (ICAM-1) is one of at least three mechanisms for lymphocyteof both lymphocyte populations (1 3 107 cells each) was injected
adhesion to cultured endothelial cells. J. Cell. Biol. 107, 321±331.i.v. into both ICAM-22/2 mice and littermate controls. 90 min later,
Eum, S.-Y., HaileÂ , S., Lefort, J., Huerre, M., and Vargaftig, B.B. (1995).the mice were sacrificed and the total number of labeled cells in
Eosinophil recruitment into the respiratory epithelium following anti-single-cell suspensions of peripheral LN sets, mesenteric LN, and
genic challenge in hyper-IgE mice is accompanied by interleukinPeyer's patches was determined by flow cytometry.
5-dependent bronchial hyperresponsiveness. Proc. Natl. Acad. Sci.
USA 92, 12290±12294.Acknowledgments
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